Primary Endpoint: Incidence of Treatment Emergent Adverse Events

All subjects who received any amount of study drug (Safety Population) were included in the safety analyses. Subjects who received the wrong study drug for the entire course of treatment were analyzed in the treatment group based on the study drug received.

The STRIVE study was not powered for inferential statistics. The number and percentage of subjects with incidence of treatment emergent adverse events based on clinical chemistry, hematology and urine analysis laboratory test, vital signs, physical exams and ECG abnormalities were presented.

Treatment Arm 1: Rezafungin Group 1
Treatment Arm 2: Rezafungin Group 2
Treatment Arm 3: Caspofungin IV

	Method of Estimation	
Type of Statistical Test	Estimation parameter	Estimated value
Descriptive	Incidence	Arm 1= 87.7% Arm 2 = 92.5% Arm 3 = 80.9%